Mustang Bio (NASDAQ:MBIO) remains underfollowed despite the fact that the company has several candidates that have the potential to be major breakthroughs in some of the most notorious and hard-to-treat diseases. Following my previous MBIO
Mustang Bio: Remains Underfollowed Despite Moving Closer To Pivotal Studies
Summary
- Mustang Bio remains underfollowed despite having several therapies that have the potential to be major breakthroughs in some of the most notorious and hard-to-treat diseases.
- MBIO's share price is near the 52-week lows despite the company completing milestones and a few bullish catalysts ahead. Several programs are moving closer to their pivotal studies.
- I review some of the recent updates and discuss how they bolster my bullish outlook. In addition, I point out some of my leading downside risks.
- I take a look at charts to map out my next MBIO buy.
Biologics is a full-time healthcare investor who developed a passion for biotech and life saving therapies after working in the medical field for years. His trade focus is around innovative companies developing breakthrough therapies and/or pharmaceuticals with catalysts for potential acquisitions.
He is the leader of the investing group Compounding Healthcare. Features of the group include: Several model healthcare portfolios, a weekly newsletter, a daily watchlist, and chat for dialogue and questions. Learn more.Analyst’s Disclosure:I/we have a beneficial long position in the shares of MBIO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.